AusperBio Therapeutics — Valuation, Funding & Investors

Recent changes

Aug 27, 2026Aug 27, 2026Raised $120M Series C BioSpace

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Aug 27, 2026	Series C	$120M	—	RA Capital's new commitment	Pulse story

Latest Pulse

Aug 27, 2026AusperBio Raises $120M for Hepatitis B CureAusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.→

Coverage Timeline

newest first

Aug 27, 2026FUNDINGAusperBio Raises $120M for Hepatitis B Cure$120M Series C→

All Coverage

FUNDING· Aug 27, 2026

AusperBio Raises $120M for Hepatitis B Cure

FUNDING$120M Series C

AusperBio Raises $120M for Hepatitis B Cure

AusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.

Aug 27, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

BioSpaceValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction